A5057864168- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Advanced Breast Cancer Therapies
- Endometrial and Cervical Cancer Treatments
- Lung Cancer Treatments and Mutations
- HER2/EGFR in Cancer Research
- Melanoma and MAPK Pathways
- Radiomics and Machine Learning in Medical Imaging
- Cancer Cells and Metastasis
- Cancer-related molecular mechanisms research
- Colorectal and Anal Carcinomas
- Breast Cancer Treatment Studies
- PI3K/AKT/mTOR signaling in cancer
- Cancer Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Lung Cancer Diagnosis and Treatment
- Inflammatory Biomarkers in Disease Prognosis
- Monoclonal and Polyclonal Antibodies Research
- Genetic factors in colorectal cancer
- CAR-T cell therapy research
- Cancer-related Molecular Pathways
- Erythrocyte Function and Pathophysiology
- Ovarian cancer diagnosis and treatment
- Blood properties and coagulation
- Cervical Cancer and HPV Research
Instituto de Investigación Sanitaria de Santiago
2019-2025
Servicio Gallego de Salud
2024-2025
Universidade de Santiago de Compostela
2022-2025
Complejo Hospitalario Universitario de Santiago
2018-2022
Centro de Investigación Biomédica en Red de Cáncer
2019
Recently, immunotherapy has changed the standard of treatment in non-small cell lung cancer (NSCLC). Outside clinical trials, data real life is lacking. This an observational study that represents world experience with nivolumab pretreated NSCLC.Eligibility criteria included, histologically confirmed NSCLC, stage IIIB and IV, evaluable disease at least one prior therapy. Patients received until progressive (PD) or unacceptable toxicity. The main aim was to report efficacy safety profile...
The lung immune prognostic index (LIPI) has been proposed as a new categorical blood-based biomarker to select advanced non-small cell cancer (NSCLC) patients for anti-programmed death-1 (PD-1) or programmed death ligand 1 (PD-L1) therapy. In this study, we investigate the first time best of our knowledge and predictive utility LIPI in multicenter nivolumab monotherapy-based cohort. We retrospectively analyzed influence baseline on overall survival (OS), progression-free (PFS), disease...
A critical step in the metastatic cascade is survival of circulating tumor cells (CTCs) within bloodstream. Although interactions between CTCs and various hematopoietic have been described, role red blood (RBCs) remains underexplored. This study investigated RBCs from breast lung cancer patients, revealing significant phenotypic functional changes cells, unlike with healthy donors. Tumor cell patient-derived RBC co-cultures increased attachment induced morphological changes. RBC-primed...
Metastatic breast cancer (BC) is the main cause of cancer-related mortality in women worldwide. HR + /HER2- BC patients are treated with endocrine therapy (ET), but therapeutic resistance common. The combination cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) ET was approved for metastatic and extended median progression-free survival to 24 months. This not always effective, every patient, ultimately occurs, underlying mechanisms remain unclear. To address this gap, we explored circulating...
Endometrial cancer (EC) is the 4th most common neoplasm of female genital tract, with 15–20% patients being high risk recurrence which leads to a significant decrease in patient survival. Current therapeutic options for EC are poor, combined therapy carboplatin and paclitaxel standard care, limited efficacy. Therefore, new better monitoring tools needed improve management disease. In current case report, we showcase value liquid biopsy analyses microsatellite instability initially good...
Abstract Background The combination of trastuzumab, pertuzumab (HP) and a taxane increases progression-free survival (PFS) overall (OS) in patients with HER2-positive (HER2+) advanced breast cancer (BC). PIK3CA mutations can occur 30-35% HER2+ tumors, independently hormone receptor (HR) status. In an exploratory analysis from CLEOPATRA, tumor harboring mutation (mut) had shorter PFS. AKT inhibitor ipatasertib (IPAT) blocks the PI3K/AKT pathway has activity PI3K/AKT-altered tumors. We...
<h3>Introduction/Background</h3> Minimally invasive biomarkers allow for the dynamic characterization of disease. In past years, there has been a rise on advanced endometrial cancers (EC) patients resulting in an increase mortality rates. This clinical paradigm highlights need to find prognostic that helps identify those with worse prognosis. <h3>Methodology</h3> Plasma samples and uterine aspirate (UA) from 148 EC were collected different hospitals within Spain at baseline throughout course...
ABSTRACT Introduction In the past years, there has been a rise on advanced endometrial cancers (EC) patients resulting in mortality increase. To overcome this trend, it is essential to improve stratification of risk post-surgery recurrence and anticipate development disease relapse resistance treatment. Liquid biopsy analyses represent promising tool address these clinical challenges, however, best strategy efficiently apply them context EC must be better defined. Therefore, study was...
Abstract Background The combination of HP and a taxane increases progression-free survival (PFS) overall (OS) in patients with HER2+ ABC. PIK3CA mut can occur 30-35% tumors, independently hormone receptor (HR) status. In an exploratory analysis from CLEOPATRA, tumor harboring had shorter PFS. AKT inhibitor IPAT blocks the PI3K/AKT pathway has activity PI3K/AKT-altered tumors. Patients Methods IPATHER (NCT04253561) is open-label, single-arm, phase Ib study to evaluate safety preliminary...
e20645 Background: The lung immune prognostic index (LIPI) has been proposed as a new biomarker to select advanced non-small cell cancer (NSCLC) patients for anti-programmed death-1 or programmed death ligand 1 therapy. In this study, we investigate the and predictive utility of LIPI in multicentric nivolumab monotherapy-based cohort. Methods: 153 with available baseline were included. Survival estimates calculated by Kaplan-Meier method, groups compared log-rank test. impact on survival...